Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility

Bibliography

• KANNEL WB, ABBOTT RD, SAVAGE DD et al.: Epidemiological features of chronic atrial fibrillation: the Framingham study. N Engl. I Med. (1982) 306:1018–1022.
   PubMed Web of Science ®Google Scholar
• BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA (1994) 271:840–844.
   PubMed Web of Science ®Google Scholar
• BAILY D, LEHMANN MH, SCHUMACJER DN et al.: Hospitalization from arrhythmias in the United States: importance of atrial fibrillation. I Am. Coll Cardiol (1992) 19:41A.
   Google Scholar
• BENJAMIN EJ, WOLF PA, D'AGOSTINO RB et al.: Impact of atrial fibrillation on the risk of death: the Framingham Study. Circulation (1998) 98:946–952.
   PubMed Web of Science ®Google Scholar
• FREESTONE B, LIP GYH: Management of acute and recent-onset atrial fibrillation. Evidence-Based Cardiovascular Medicine (2003) 7:111–116.
   PubMedGoogle Scholar
• HOHNLOSER SH, KUCH KH, LILENTHAL J: Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) — a randomized trial. Lancet (2000) 356:1789–1794.
   PubMed Web of Science ®Google Scholar
• VVYSE DG, WALDO AL, DIMARCO JPet al.: Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A control of rate control and rhythm control in patients with atrial fibrillation. N Engl. Med. (2002) 347:1825–1833.
   Google Scholar
• VAN GELDER IC, HAGENS VE, BOSKER HA et al.: Rate control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl. Med. (2002) 347:1834–1840.
   Google Scholar
• KUBEC G, MALOWANY L: Functionalcapacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can. Cardiol. (1992) 8:941–946.
   PubMed Web of Science ®Google Scholar
• DELANGEN CDJ, VAN DEN BERG MP, HAAKSMA J et al.: Autocorrelation of AA intervals in artificially induced atrial fibrillation in the porcine heart. In: Atrial Mechanisms and Therapeutic Strategies. SB Olsson, MA Allessi, RWF Campbell (Eds). Futura Publising, Co., Armonk, NY (1994):51–66.
   Google Scholar
• WIJFFELS MC, KIRCHHOF CJ, DORLAND R et al.: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation (1995) 92:1954–1968.
   PubMed Web of Science ®Google Scholar
• KONINGS KT, KIRCHHOF CJ, SMEETS JR et al.: High density mapping of electrically induced atrial fibrillation in humans. Circulation (1994) 89:1665–1680.
   PubMed Web of Science ®Google Scholar
• WALDO AL, MacLEAN WAH, COOPER TB et al: The use of temporarily placed epicardial leads atrial wire lectrodes for the diagnosis and treatment of cardiac arrhythmias following open heart surgery. Thorac. Cardiovasc. Surg. (1978) 76:500–505.
   Web of Science ®Google Scholar
• WELLS LJ JR, KARP RB, KOUCHOUKOS NT et al.: Catheterization of atrial fibrillation in man: studies following open heart surgery. PACE (1978) 1:426–438.
   Google Scholar
• PANDOZI C, SANTINI M: Update on atrial remodeling owing to rate; does atrial fibrillation always beget atrial fibrillation? Eur. Heart (2001) 22:541–553.
   Web of Science ®Google Scholar
• •Describes electrical remodelling of the atria secondary to rapid heart rate, the basis of self perpetuation of AE
   Google Scholar
• LAI LP, SU MJ, UN JL et al.: Down- regulation of the sarcoplasmic reticular Ca2+-ATPase mRNA of ryanodine receptor, calsequestrin and phosphorylation: an insight into the mechanism of atrial remodelling. Am. Coll. Cardiol (1999) 33:1231–1237.
   PubMed Web of Science ®Google Scholar
• MORILLO CA, KLEIN GJ, JONES DL et al.: Chronic rapid atrial pacing: structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation (1995) 91:1588–1595.
   PubMed Web of Science ®Google Scholar
• SANFILIPPO AJ, ABASCAL VM, SHEHAN M et al.: Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 82:792–797.
   PubMed Web of Science ®Google Scholar
• ALLESSIE MA BOYDEN PA, CAMM AJ et al.: Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 103:769–777.
   Google Scholar
• REISINGER J, GATTERER E, HEINZE G et al.: Prospective comparison of flecainide versus sotalol for immediate cardioversion of AF. Am. Cardiol (1998) 81:1450–1454.
   PubMed Web of Science ®Google Scholar
• BOTTO GL, POLITI A, BONINI W et al.: External cardioversion of atrial fibrillation: role of paddle position on technical efficiency and energy requirements. Heart (1999) 82:726–730.
   PubMed Web of Science ®Google Scholar
• TIELMAN RG, VAN GELDER IC, CRIJNS HJ et al.: Early recurrence of atrial fibrillation after electrical cardioversion: a result of atrial fibrillation-induced electrical remodeling of the atria?" Am. Coll. Cardiol (1998) 31:167–173.
   PubMed Web of Science ®Google Scholar
• BOTTO GL, BELOTTI G, CIRO A et al:Verapamil pretreatment before electrical cardioversion of persistent atrial fibrillation: the VERAF Study. Eur: Heart (2001) 22:239.
   Google Scholar
• •Due to its effects on electrical remodelling, pre-treatment with veraparnil significantly reduces the immediate recurrence (within 7 days) of AF following successful electrical cardioversion, but has no effect on long-term recurrences.
   Google Scholar
• PERDERSEN OD, BAQQER H, KOBER L et al.: Trandalapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100:376–380.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA H, KUMAQAI K, URATA H et al: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 101:2612–2617.
   PubMed Web of Science ®Google Scholar
• •Beneficial effects of angiotensin receptor antagonists in preventing atrial remodelling and their possible role in the maintenance of sinus rhythm as part of polytherapy.
   Google Scholar
• MADRID AH, BUENO MG, REBOLLO JMG et al: Use of irbesartan to maintain sinus rhythm in patients with longstanding atrial fibrillation. Circulation (2002) 106:331–336.
   PubMed Web of Science ®Google Scholar
• •See [25].
   Google Scholar
• AZPITARTE J, ALVARES M, BAUN 0 et al.: Value of single oral loading dose propafenone in converting recent onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur. Heart. (1997)18:1649–1654.
   Google Scholar
• CAPUCCI A, VILLANI GQ, ASCHIERI D et al: Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multi-center study. Int. Cardiol (1999) 68:187–196.
   PubMed Web of Science ®Google Scholar
• SUTTORP MJ, KINGMA JH, JESSURUN ER et al.: The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. I Am. Coll. Cardiol (1990)16:1722–1727.
   PubMed Web of Science ®Google Scholar
• SUTTORP MJ, KINGMA JH, JESSURUN ER et al.: Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am. Cardiol (1989) 63:693–696.
   PubMed Web of Science ®Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl. I Med. (1989) 321:406–412.
   PubMed Web of Science ®Google Scholar
• LINDELL P, SVENARUD P, ALBAGE A et al.: Electrical conversion of atrial fibrillation. Superior effects of biphasic transthoracic method when compared with the conventional monophasic method. Lakartidningen (2001) 98:3319–3321.
   Google Scholar
• HOROWITZ UN, SPELMAN SR, GREENSPAN AM et al: Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. I Am. Coll. Cardiol (1985) 6:1402–1407.
   PubMed Web of Science ®Google Scholar
• TUZCU EM, GILBO J, MASTERSON M et al.: The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve. Clin. I Med. (1989) 56:238–242.
   PubMed Web of Science ®Google Scholar
• KOCHIADAKIS GE, IGOUMENDIS NE, MARKETOU ME et al.: Low dose amiodarone and sotalol in the treatment of recurrent symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart (2000) 84:251–257.
   PubMed Web of Science ®Google Scholar
• ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl. Med. (2000) 342:913–920.
   Google Scholar
• •Amiodarone is more effective in maintaining sinus rhythm following successful cardioversion compared with sotalol and propafenone.
   Google Scholar
• FARSHI R, KISTNER D, SARNIA JSH et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise. A crossover open-label study of five drug regimens. Am. Coll. Cardiol (1999) 33:304–310.
   PubMed Web of Science ®Google Scholar
• YAMASHITA T, MURAKAWA Y, SEZAKI K et al: Uniqueness of pilsicainide in class Ic antiarrythmics. fpn Heart (1998) 39:389–397.
   Web of Science ®Google Scholar
• KOHNO K, TAKEUCHI Y, GOMI A et al.: Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting. fpn Thome. Cardiovasc. Stow. (1998) 46(4):361–367.
   PubMedGoogle Scholar
• ATARSHI H, INOQUE H, HIEJIMA K et al.: Conversion of recent onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Supression Trial on Atrial Fibrillation). The PSTAF
   Google Scholar
• •• Investigators. Am.,/ Cardiol (1996) 78:694–697.
   Google Scholar
• •Oral pilsicainide superior to disopyrarnide in terminating persistent AE
   Google Scholar
• KUMAGAI K, ABE H, HIRAKI T et al.: Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pacing Clin. Electrophysiol (2000) 23:1880–1882.
   PubMed Web of Science ®Google Scholar
• KOMATSU T, NAKAMURA S, KIMURA M et al.: Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset J. Cardiol (2001) 38:211–217.
   Google Scholar
• OKISHIGE K, NISHIKAZI M, AZEGAMI K et al.: Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled multicenter study. Am. Heart J. (2000) 140:437–444.
   Google Scholar
• •Pretrearnent with pilsicainide is significantly more effective in cardioverting chronic AF (compared with placebo) and moderately effective in maintaining sinus rhythm.
   Google Scholar
• NUMATA T, ABE H, NAGATOMO T, KOHSHI K et al.: Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. fpn Circ. (2000) 64:750–754.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA K, ISHIKAWA T, SUMITA S et al.: Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride. Cardiol (2003) 42:81–86.
   Google Scholar
• BASKIN EP, LYNCH JJ Jr: Comparative effects of increased intracellular potassium and pacing frequency on the class III activities of methanesulfonanilide Ikr blockers dofetilide, D-sotalol, E-4031 and MK-499.j Cardiovasc. Pharmacol (1994) 24:199–208.
   PubMed Web of Science ®Google Scholar
• FALK RH, POLLAKA, SINGH SN et al:Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J. Am. Coll. Cardiol (1997) 29:857–865.
   Google Scholar
• NOGAARD BL, WACHTELL K, CHRISTENSEN et al.: Efficacy and safety of intravenously administered dofetilide in acute termination of atrialfibrillation and flutter: a multicenter, randomised, double-blind, placebo-controlled trail. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J. (1999) 137:1062–1069.
   Google Scholar
• GREENBAUM RA, CAMPBELL TJ, CHANNER KS et al.: Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study. Circulation (1998) 98:1633.
   Google Scholar
• SINGH S, ZOBLE RG, YELLEN L et al: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385–2390.
   PubMed Web of Science ®Google Scholar
• ••Oral dofetilide is moderately effective inpharmacological cardioversion of persistent AF and significantly effective in maintaining sinus rhythm.
   Google Scholar
• BIANCOLI L, CASTRO A, DINELLI M et al.: Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, placebo-controlled study. Rut: Heart J. (2000) 21:1265–1273.
   Google Scholar
• TROP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. N Engl. J. Med. (1999) 34:857–865.
   Google Scholar
• ••Dofetilide reduces admission in heartfailure patients without any effects on mortality. Among a subgroup with AF dofetilide was better than placebo for cardioversion and maintenance of sinus rhythm.
   Google Scholar
• ELLENBOGEN KA, STAMBLER BS, WOOD MA et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a dose-response study. J. Am. Coll. Cardiol (1996) 28:130–136.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA et al: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation (1996) 94:1613–1621.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, WOOD MA, ELLENBOGEN KA et al.: Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy. Circulation (1997) 96:4298–4306.
   PubMed Web of Science ®Google Scholar
• BERNARD E 0, SCHMID ER, SCHMIDLIN D et al.: Ibutilide versus amiodarone in atrial fibrillation: A double-blinded, randomized study. Grit. Care Med. (2003) 31:1031–1034.
   Google Scholar
• ORAL H, SOUZA J, MICHAUD GF et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. NT/M(1999) 340:1849–1854.
   PubMed Web of Science ®Google Scholar
• ••Success rate of direct current cardioversioncan be improved with adjunctive ibutilide therapy.
   Google Scholar
• STICHERLING C, OZAYDIN M, TADA H et al.: Comparison of verapamil and ibutilide for the suppression of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Cardiovasc. Pharmacol Ther. (2002) 7:155–160.
   PubMedGoogle Scholar
• KATHY GLATTER, YANFEI YANG, KANU CHATTERJEE et al: Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation (2001) 103:253257.
   Google Scholar
• WOOD MA, STAMBLER BS, ELLENBOGEN KA et al.: Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Am. Heart J. (1998) 135:1048–1054.
   PubMed Web of Science ®Google Scholar
• STAMBLER BS, BECKMAN KJ, KADISH AH et al.: Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am. J. Cardiol (1997) 80:458–463.
   PubMed Web of Science ®Google Scholar
• BERGER F, BORCHARD U, HAFNER D et al.: Different inhibition patterns of tedisamil for fast and slowly activation transient outward current in rat ventricular myocytes. Naunyn-schiedeberg's Arch. Pharm. (1998) 357:291–298.
   PubMed Web of Science ®Google Scholar
• DUKES ID, CLEEMANN L, MORAD M: Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. Pharmacol Exp. Thec (1990) 254:560–569.
   PubMed Web of Science ®Google Scholar
• FAIVRE JR, BRIL A: Tedisamil inhibitionof ATP- sensitive K+ channels in adult rat ventricular cells. J. MM. Cell. Cardiol (1992) 24:S40.
   Google Scholar
• DUCHOSAL F, OPIE H: KC8857, a new compound with combined bradycardic and positive inotropic effects. j Mol.
   Google Scholar
• •• Cardiol (1987) 19(Suppl. III) (Abstract 19).
   Google Scholar
• FUCHS A, BUSCHMANN G, ZEIGLER D et al.: Tedisamil: cardiac electrophysuiologic and functional effects in guinea pigs. Naunyn-schiedeberg's Arch. Pharm. (1989) 340:R72.
   Google Scholar
• FOX KM, HENDERSON JR, KASKI JC et al.: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart (2000) 83:167–171.
   PubMed Web of Science ®Google Scholar
• • Tedisamil is effective in improving exercise capacity and reducing anginal episodes in patients with stable angina.
   Google Scholar
• FRIEDRICHS GS, ABREU JN, DRISCOLL EM et al.: Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. Cardiovasc. Pharmacol (1998) 31:56–66.
   PubMed Web of Science ®Google Scholar
• FISCHBACH PS, JOHNSTON PV, FRIEDRICHS GS et al.: Tedisamil in a chronic canine model of atrial flutter. Cardiovasc. Pharmacol (1999) 34:212–218.
   PubMed Web of Science ®Google Scholar
• FISCHBACH PS, BARRETT TD, GOYAL R et al: Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.' Cardiovasc. Electrophysiol (2001) 12:1138–1144.
   PubMed Web of Science ®Google Scholar
• KOWEY PR, DORIAN P, BECKMANN K et al.: Tedisamil for rapid conversion of recent onset atrial fibrillation and flutter to normal sinus rhythm. The North American Society of Pacing and Electrophysiology (NASPE) Washington, USA (2003) (Abstract 417).
   Google Scholar
• NISHIDA A, UMERA H, OGURA T et al.: Inhibitory effects of azimilide on KE currents in isolated guinea-pig cardiomyocytes. fpn Pharmacol (2000) 82:217.
   Google Scholar
• NATTEL S, LIU L, ST GEORGES D: Effects of novel antiarrhythmic agent azimilide on experimental atrial fibrillation and electrophysiologic properties. Cardiovasc. Res. (1998) 37:627–635.
   PubMed Web of Science ®Google Scholar
• CONNOLLY SJ, SCHNELL DJ, PAGE RL et al.: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. Cardiol Nov (2001) 88/9:974–979.
   Google Scholar
• SORELLE R ALIVE Trial. Circulation (2001) 104:E9053–E9055.
   PubMedGoogle Scholar
• SINGER I, AL-KHALIDI H, NIAZI I et al.: Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Am. Coll. Cardiol (2004) 43:39-43. Azimilide is safe in patients with left ventricular dysfunction and decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
   Google Scholar
• LEE J H, ROSENSHTRAUKH L, BLOSHAPKO G et al: The electrophysiologic effects of ersentilide on canine hearts. Eur: Pharmacol (1995) 285:25–35.
   PubMed Web of Science ®Google Scholar
• ADAMSON PB, VANDI E, HULL SS et al.: Antifibrillatory efficacy of ersentilide, a novel beta adrenergic and /K. blocker in conscious dogs with healed myocardial infarction. Cardiovasc. Res. (1998) 40:56–63.
   Google Scholar
• MATSUO R, SHIRAYAMA T, INOUE K et al.: 5D3212, a new antiarrhythmic drug raises the atrial fibrillation threshold in rabbit hearts. Heart Vessels (1999) 14:127-136. ao. HASHIMOTO H, UMEMURA K, ARAKI S et al.: Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. Biol. Pharm. Bull. (1994) 17:548–550.
   Google Scholar
• GAUTIER-P, GUILLEMARE E, MARION A et al.: Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. " Cardiovasc. Pharmacol (2003) 41:191–202.
   Google Scholar
• LALEVa N, BARRE. RE LEMAIRE S, GAUTIER P et al.: Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. Cardiovasc. Electrophysiol (2003) 14:885–890.
   Google Scholar
• SUN W, SARMA JSM, SINGH BN: Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. Cardiovasc. Pharmacol (2002) 39:677–684.
   PubMed Web of Science ®Google Scholar
• •Dronedarone has similar acute electrophysiological effects as amiodarone.
   Google Scholar
• PANTOS C, MOUROUZIS I, DELBRUYE. RE M et at. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Ear. Pharmacol (2002) 444(3):191–196.
   Google Scholar
• TOUBOUL P, BRUGADA J, CAPUCCI A et al.: Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur: Heart J. (2003) 24:1481–1487.
   PubMed Web of Science ®Google Scholar
• JAHNEL U, RUPP J, ERTL R et al: Positive inotropic response to 5-HT in human atrial but not ventricular heart muscle. Naunyn Schmiedbergs Arch. Pharm. (1992) 346:482–485.
   PubMed Web of Science ®Google Scholar
• KAUMANN AJ: Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci. (1994) 15:451–455.
   Google Scholar
• NATTEL S, BLASIO E, BEATCH GN et al: RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Ear. Heart J. (2001) 22\(Suppl. 448).
   Google Scholar
• BILLMAN GE: RSD1235. Cardiome. Carr: Opin. Investig. Drugs (2003) 4(3):352–354.
   PubMedGoogle Scholar
• BEATCH GN, SHINAGAWA K, JOHNSON BD et al: RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. S. World Congr. Pharmacol (2002) 24:(Abstract 21.11).
   Google Scholar
• BEATCH GN, SHINAGAWA K, JOHNSON BD et al.: Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovasc. Drugs Ther: (2002) 16:(Suppl. 149).
   Google Scholar
• Cardiome drug effective for heart patients. Cardiome Pharma Corp. Press Release 2002 September 2002.
   Google Scholar
• WU L, BELARDINELLI L, ZABLOCKI J et al.: A partial agonist of the Al-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. .1. Physic] Heart Circ. Physiol (2001) 280:334–343.
   Google Scholar
• ERGA KS, SEUBERT CN, LIANG HX et al.: Role of A2A-adenosine receptor activation for ATP-mediated coronary vasodilation in guinea-pig isolated heart. Br. Pharmacol (2000) 130:1065–1075.
   PubMed Web of Science ®Google Scholar
• SNOWDY S, LIANG H, BLACKBURN B et al.: A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Br. J. Pharmacol (1999) 126:137–146.
   PubMed Web of Science ®Google Scholar
• COPLEN SE, ANTMAN EM, BERLIN JAet al.: Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized controlled trials. Circulation (1990) 82:1106–1116.
   Google Scholar
• MOSS AJ, DAVIS HT, CONARD DL et al.: Digitalis associated mortality after myocardial infarction. Circulation (1981) 64:1150–1156.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, OEHM E, THORIVIANN J et al.: Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease. Clin. Cardiol (1998) 21:492-502. Affiliation
   Google Scholar